NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
18.40
-0.08 (-0.43%)
At close: Jul 19, 2024, 4:00 PM
18.09
-0.31 (-1.68%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
NovoCure Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for NovoCure stock have an average target of 30, with a low estimate of 17 and a high estimate of 51. The average target predicts an increase of 63.04% from the current stock price of 18.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 1 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 4 | 4 | 4 | 4 | 3 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $15 → $20 | Hold | Maintains | $15 → $20 | +8.70% | Jul 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $22 | Hold | Reiterates | $22 | +19.57% | Jun 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $24 → $22 | Hold | Maintains | $24 → $22 | +19.57% | May 2, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $25 → $28 | Buy | Reiterates | $25 → $28 | +52.17% | Apr 10, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $49 → $42 | Buy | Maintains | $49 → $42 | +128.26% | Apr 3, 2024 |
Financial Forecast
Revenue This Year
565.21M
from 509.34M
Increased by 10.97%
Revenue Next Year
608.55M
from 565.21M
Increased by 7.67%
EPS This Year
-1.66
from -1.95
EPS Next Year
-1.76
from -1.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 595.4M | 647.3M | 772.8M | 832.8M | 991.9M |
| Avg | 565.2M | 608.6M | 693.6M | 763.0M | 963.6M |
| Low | 532.0M | 569.8M | 599.0M | 688.9M | 925.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.9% | 14.5% | 27.0% | 20.1% | 30.0% |
| Avg | 11.0% | 7.7% | 14.0% | 10.0% | 26.3% |
| Low | 4.5% | 0.8% | -1.6% | -0.7% | 21.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.46 | -1.49 | -1.39 | -1.13 | -0.90 |
| Avg | -1.66 | -1.76 | -1.68 | -1.35 | -0.88 |
| Low | -1.75 | -1.99 | -2.04 | -1.53 | -0.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.